Arcus Biosciences Releases Kidney Cancer Drug Results

The company reported new findings from clinical trials testing casdatifan as a treatment for renal cell carcinoma.

Updated on Oct. 20, 2026 in Biotech

Arcus Biosciences Releases Kidney Cancer Drug Results

Live Poll

Do you trust the initial trial results reported by small pharmaceutical companies?

Arcus Biosciences has released clinical trial results for its investigational kidney cancer drug, casdatifan. The drug targets renal cell carcinoma in patients across multiple treatment lines.

Why it matters

The clinical trial results provide insight into the efficacy of casdatifan when used alone or in combination therapy for patients with renal cell carcinoma. The data spans first, second, and later lines of treatment to assess the drug's potential utility in various stages of patient care.

Arcus Biosciences tested casdatifan as a monotherapy and in combination treatments across multiple patient datasets. The drug is designed to address renal cell carcinoma through various lines of intervention.

The players

Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company headquartered in the United States that develops therapies for cancer.

The details

The study evaluated casdatifan for treating renal cell carcinoma by testing it as a first, second, and later line of therapy. Researchers observed the performance of the drug when administered alone and in combination with other therapeutic agents.

October 20, 2026: Arcus Biosciences released the trial results for casdatifan.

The Tech Race

This release positions Arcus Biosciences within the competitive development of targeted treatments for renal cell carcinoma. The study follows an industry trend of moving away from generalized chemotherapy toward specialized inhibitors.

While the drug remains in the clinical trial phase, these results clarify the potential for future treatment options for kidney cancer patients. Following the announcement, Arcus Biosciences shares experienced a decline of a single-digit percentage.

The takeaway

Clinical trial data helps physicians and researchers determine which therapeutic combinations offer the most promise for patient recovery. Patients and investors should continue to monitor future trial milestones to see if these results translate into an approved clinical therapy.